CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade United Therapeutics Corp - UTHR CFD

359.28
0.11%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon: 14:30 - 21:00

Tue: 14:30 - 18:00

Thu - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.84
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023374 %
Charges from full value of position ($-0.23)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023374%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001151 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001151%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 359.69
Open 359.3
1-Year Change 49.38%
Day's Range 357.49 - 362.8
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 20, 2024 359.28 0.32 0.09% 358.96 363.05 357.49
Dec 19, 2024 359.69 2.27 0.64% 357.42 364.62 350.34
Dec 18, 2024 357.03 -19.92 -5.28% 376.95 382.26 355.40
Dec 17, 2024 379.33 7.37 1.98% 371.96 381.59 371.96
Dec 16, 2024 372.33 12.30 3.42% 360.03 372.92 360.02
Dec 13, 2024 361.32 1.63 0.45% 359.69 362.64 358.51
Dec 12, 2024 361.34 -1.62 -0.45% 362.96 363.94 359.95
Dec 11, 2024 361.89 2.36 0.66% 359.53 364.96 358.50
Dec 10, 2024 361.99 -5.19 -1.41% 367.18 367.36 358.37
Dec 9, 2024 366.58 -0.71 -0.19% 367.29 371.03 362.51
Dec 6, 2024 369.24 -1.80 -0.49% 371.04 377.72 367.06
Dec 5, 2024 373.82 3.67 0.99% 370.15 376.74 369.95
Dec 4, 2024 373.93 5.20 1.41% 368.73 374.63 366.69
Dec 3, 2024 368.91 -0.04 -0.01% 368.95 371.10 364.95
Dec 2, 2024 369.74 -2.21 -0.59% 371.95 375.28 366.39
Nov 29, 2024 370.34 -4.61 -1.23% 374.95 378.38 369.96
Nov 27, 2024 377.96 3.94 1.05% 374.02 380.15 370.01
Nov 26, 2024 376.72 7.76 2.10% 368.96 377.91 366.44
Nov 25, 2024 368.48 -4.68 -1.25% 373.16 375.88 368.13
Nov 22, 2024 372.58 6.15 1.68% 366.43 373.77 366.43

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

United Therapeutics Company profile

About United Therapeutics Corporation

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat ulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). It also includes technologies designed supply of transplantable organs and tissues and improves outcomes for transplant recipients through regenerative medicine, three-dimensional (3-D) organ bioprinting, xenotransplantation and ex-vivo lung perfusion.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, United Therapeutics Corporation revenues increased 14% to $1.69B. Net income decreased 8% to $475.8M. Revenues reflect Tyvaso segment increase of 26% to $607.5M, Unituxin segment increase of 65% to $202.3M, United States segment increase of 11% to $1.56B, Rest-of-World segment increase of 70% to $121.3M. Net income was offset by IPR&D asset impairment charges increase from $0K to $113.4M (expense).

Equity composition

Common Stock $.01 Par, 06/11, 245M auth., 60,817,983 issd., less 2,503,657 shs. in Treas. @ $70.1M. Insiders control 1.10%. IPO: 6/17/99, 4,500,000 @ $12 by Deutsche Banc Alex. Brown. 09/09, 2-for-1 stock split.

Industry: Biotechnology & Medical Research (NEC)

1000 Spring St
SILVER SPRING
MARYLAND 20910
US

People also watch

US100

21,409.50 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 22:00 (UTC)
Spread 1.8

Gold

2,625.43 Price
-0.070% 1D Chg, %
Long position overnight fee -0.0151%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

2.14 Price
-3.760% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01066

ETH/USD

3,238.01 Price
-1.940% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading